June 30, 2020 / 12:20 PM / 15 days ago

BRIEF-Ardelyx Announces Submission Of NDA To U.S. FDA For Tenapanor In Adults With CKD On Dialysis

June 30 (Reuters) - Ardelyx Inc:

* ARDELYX ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FDA FOR TENAPANOR FOR THE CONTROL OF SERUM PHOSPHORUS IN ADULT PATIENTS WITH CKD ON DIALYSIS

* ARDELYX INC - EXPECTS TO RECEIVE NOTIFICATION FROM FDA ON ACCEPTANCE OF FILING FOR SUBSTANTIVE REVIEW IN LATE AUGUST 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below